Cancer esearch apeutics , Targets , and Chemical Biology tinib ( YN 968 D 1 ) Reverses Multidrug Resistance by biting the Efflux Function of Multiple ATP-Binding R sette Transporters
Yan-ju,Li-yan,Kenne,N. Mi,Yong‐ju Liang,Hong-bing Huang,Hong-yun Zhao,Chung-Pu Wu,Fang Wang,G. Tao,Chuan-zhao Zhang,Chun-ling Dai,A. Tiwari,Xiao-xu Ma,T.H.W. To,S. Ambudkar,Zhe-Sheng Chen
2010-01-01
Abstract:Downlo tinib, a small-molecule multitargeted tyrosine kinase inhibitor, is in phase III clinical trial for the treatf patients with non–small-cell lung cancer and gastric cancer in China. In this study, we determined the of apatinib on the interaction of specific antineoplastic compounds with P-glycoprotein (ABCB1), mulresistance protein 1 (MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2). Our results d that apatinib significantly enhanced the cytotoxicity of ABCB1 or ABCG2 substrate drugs in KBv200, /adr, and HEK293/ABCB1 cells overexpressing ABCB1 and in S1-M1-80, MCF-7/FLV1000, and HEK293/ 2-R2 cells overexpressing ABCG2 (wild-type). In contrast, apatinib did not alter the cytotoxicity of speubstrates in the parental cells and cells overexpressing ABCC1. Apatinib significantly increased the inlular accumulation of rhodamine 123 and doxorubicin in the multidrug resistance (MDR) cells. rmore, apatinib significantly inhibited the photoaffinity labeling of both ABCB1 and ABCG2 with [I] ylazidoprazosin in a concentration-dependent manner. The ATPase activity of both ABCB1 and ABCG2 gnificantly increased by apatinib. However, apatinib, at a concentration that produced a reversal of MDR, t significantly alter the ABCB1 or ABCG2 protein or mRNA expression levels or the phosphorylation of nd extracellular signal–regulated kinase 1/2 (ERK1/2). Importantly, apatinib significantly enhanced the of paclitaxel against the ABCB1-resistant KBv200 cancer cell xenografts in nude mice. In conclusion, ib reverses ABCB1and ABCG2-mediated MDR by inhibiting their transport function, but not by blocking apatin the AKT or ERK1/2 pathway or downregulating ABCB1 or ABCG2 expression. Apatinib may be useful in circumventing MDR to other conventional antineoplastic drugs. Cancer Res; 70(20); 7981–91. ©2010 AACR.